Axovant shares leap on promising gene therapy data

Sio Gene Therapies

23/10/2019 18:34

** Gene therapy developer's shares  AXGT.O  up as much as
16.8% at $6.45 - on track for their biggest one-day pct jump in
4 months
    ** Co posts promising data from a small trial of its gene
therapy in children with rare, inherited disorder
Tay-Sachs urn:newsml:reuters.com:*:nGNX9SL222
    ** Tay-Sachs causes progressive loss of muscle control in
children, leading to paralysis, blindness and death in some
cases 
    ** AXGT says the data from two patients indicates the
therapy has potential to modify the rate of the disease's
progress 
    ** Jefferies analyst Michael Yee says data are encouraging
and support eventually moving to a late-stage trial 
    ** Wednesday's rise cuts YTD losses to about 21% 

 (Reporting by Tamara Mathias in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 806749 8325))